For further details see:
Atossa Therapeutics gets regulatory nod for AT-H201 COVID-19 study in AustraliaFor further details see:
Atossa Therapeutics gets regulatory nod for AT-H201 COVID-19 study in AustraliaMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.96%Change Percent:
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...